Condition
Glucocorticoid-induced Osteoporosis
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 3 (1)
P 4 (2)
Trial Status
Completed2
Withdrawn1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06588153Phase 4RecruitingPrimary
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT04091243Phase 4CompletedPrimary
Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
NCT03164928Phase 3Completed
Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
NCT02418273Phase 1Withdrawn
Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
Showing all 4 trials